Health Archive » February, 2012

Health - February, 2012

290 articles

• HHS Finds $1B in Home Health Medicare Claims Miss Data
• 3rd Circ. Says AIG Unit Doesn't Owe Hospital Group Coverage
• Consumer Groups Say Aneurysm Fixer Needs More FDA Tests
• Abbot Targets Amneal In Latest Suit Over Generic Niaspan
• Bill Would Create Registry Of Legit Web Pharmacies
• Indie Pharmacies Claim CMS Rule Stifles Competition
• Current Trends In Health Care Fraud Enforcement
• House Panel Votes To Kill Health Law's Medicare Costs Board
• Ex-Exec Can't Support FCA Claims, Pfizer Tells 1st Circ.
• Dainippon To Pay Up To $2.6B For Cancer Drug Developer
• GOP Lawmakers Lash Out At Employer Contraception Rule
• Bayer, Others Exit Price-Fixing Suit After High Court Win
• Fresenius Must Sell Clinics To Finish $2B Liberty Buy: FTC
• Businesses Urge Delay Of Health Benefit Explanations
• Families Toss Bid To Renew J&J, Omnicare Antitrust Suit
• Statins Carry Small Risk Of Diabetes, FDA Warns
• Merck Failed To Probe Diabetes Drugs For Risks: FDA
• Eisai Can't Pry Transcripts From 2003 Aventis Antitrust Suit
• Insurer Seeks To Toss Perkins Coie Atty's Testimony
• Sebelius, Lawmakers Spar Over Long-Term Medicare Solvency
• Invalidity Claim To Be Tried In Pitt, Varian Patent Fight
• Feds Charge Doctor In $375M Medicare Fraud
• Abbott Lodges New Zemplar Patent Suit Against Hospira
• Lawmakers Mull Wasteful Spending Revealed In GAO Report
• Diagnostics Co. Alere To Acquire EScreen For $270M
• Marine Polymer — Take 2
• Doctors Urge Hill To Get Rid Of Payment Advisory Board
• FDA Warnings Don't Always Start Limitations Clock: NJ Court
• Mandarin Capital Triples Investment In Italian Pharma Co.
• Buying Groups Shook Down Vaccine Customers, Sanofi Says
• Mylan Ends Calif. Drug Price Inflation Claims For $57M
• FDA Rejects Preterm Birth Drug From Watson, Columbia
• Glenmark Recalls Birth Control Over Faulty Packaging
• FTC To Challenge Ga. Hospital Merger In High Court
• Bradley Arant Snags Health Atty From Balch & Bingham
• HHS Proposes Specs For Health Plan 'Metal Tiers'
• Shareholders Win Cert. In Suit Over Matrixx Cold Medicine
• High Court Again Denies Bid To Argue For Kagan Recusal
• The Changing Face Of US Health Care
• Where Is The Corporate Integrity Agreement?
• Hypertension Drug's Labeling Problems Prompt GSK Recall
• Blue Cross Must Face Autism Therapy Action: 6th Circ.
• Disease Groups Beg Congress For Antibiotics R&D Boost
• WellCare's $137M Medicaid Fraud Payout Clears Last Hurdle
• Part C Insurers Could Face Mandatory Fraud Reporting
• Nixon Peabody Lands Ex-Pillsbury Gov't Contracts Pro
• Warner Chilcott Subpoenaed Over Marketing, Off-Label Use
• Debtholders Can't Get $40M From US Oncology For Now
• Crowell Adds Dorsey Commercial Litigation Pro In Calif.
• Varian Hit With $37M Verdict In Pitt Patent Suit
• Regulatory Demands To Spur Health M&A in 2012: Report
• CMS Proposes Stage 2 Goals For Health E-Records
• 7 States Try To Take Down Obama Contraception Rule
• House Bill Aims To Rein In State Drug, Device Inspections
• GSK, Teva Face Antitrust Class Action Over Lamictal Deal
• 6th Circ. Scuttles Blue Cross Appeal In Antitrust Suit
• Ex-Unilab Atty Can Pursue FCA Claims, 2nd Circ. Hears
• Texas Drug Fraud Law Preempted In J&J Suit: 5th Circ.
• Carlyle Eyes Sale Of $497M Stake In Brazil's Qualicorp
• Hospital Administrator Cops To $116M Medicare Scam
• Faulty Vials Prompt Blood Pressure Med Recall
• The Pitfalls Of Paperless Discovery
• Wash.'s Contraceptive Sales Rules Unconstitutional: Judge
• New Rules Let States Opt Out Of Health Care Reform Law
• 11th Circ. Revives $69M Fraud Suit Against Medco
• Pfizer Unit Scores More Time In Ch. 11 For Asbestos Dealings
• Genetic Disorder Patients Take Aim At US Over Drug Shortages
• J&J Tries To Ease EU Concerns Over $21B Synthes Deal
• Justices Remand Challenge To Calif.'s Medicaid Cuts
• Insurer Aims To Duck Coverage Of Omeros FCA Suit
• Fla. Catholic University Sues Over Contraception Rule
• 2nd Circ. Bars Trusts From $138M Biovail, Investors Deal
• 8 States Probe Abbott's Marketing Of Anti-Seizure Drug
• SNR Denton Defamation Claims Revived In Secrets Row
• US Issues $639M In Loans For Insurance CO-OPs
• $1.7B Humira IP Verdict Won't Get Supreme Court Review
• Dental Center Co. Seeks Sale To Root Out Fraud Claims
• CMS Sunshine Rule Will Unfairly Burden Docs: AMA, Others
• Forest's COPD Drug May Have Added Heart Risks: FDA
• 13 States Back Medicaid Expansion In High Court Brief
• Allergan, Others Sought Pinkeye Treatment Monopoly: Suit
• Rotech Sues VA Over Home Oxygen Contract
• Cellectis Hit With New Genome Engineering IP Suits
• Mylan Settles Defamation Suits Against Pittsburgh Paper
• FDA Calls For Voluntary Reporting Amid Drug Shortages
• Teva To Pay $270M In Propofol Hepatitis Suits
• Genomma Bids $834M For Prestige Brands
• Schering-Plough Strikes $12.5M Deal In ERISA Suit
• High Court Nixes Nursing Home Death Arbitration Ruling
• Aetna Fires Back At Blue Cross Over Mich. Antitrust Suit
• Stop The Madness (Before It Starts): UCL Abstention
• Omnicare Abandons $441M Offer To Buy PharMerica
• Huron, Empire Can't Duck $50M St. Vincent FCA Suit
• NC Gets Health Insurance Waiver While Wis. Misses Bar
• Novartis Must Note Blood Pressure Drug Risks On EU Labels
• J&J Unit Recalls Infants' Tylenol Over Dosing Device
• Amgen Employees Press 9th Circ. To Revive ERISA Action
• Pryor Cashman Nabs IP Partner From Milbank Tweed
• PhRMA, Others Urge CMS To Back Off On Sunshine Rule
• 11th Circ. Seeks Fla. High Court's Input On Insurance Tussle
• Bird & Bird Tightens Africa Ties With Tunisian Alliance
• Bristol-Myers Subpoenaed By DOJ For Abilify Info
• Congress Passes Payroll Tax Cut, 'Doc Fix' Deal
• Increasing Access To Innovative Biomedical Technology
• In Promotional Labeling, Size Matters
• Law School, Meet Litigation PR ...
• New Bill Would Give FDA Greater Development, Review Tools
• 'Doc Fix' Deal Slashes Bad Debt Payments, Prevention Fund
• Alleged Gangster Sentenced In $100M Medicare Fraud Case
• Ex-National Century Exec's Sentence Stands: 6th Circ.
• Jury Convicts 4 In $29M Medicaid Billing Scheme
• CVS Escapes Class Action Over Health Data Sales
• Catholic Group Sues White House Over Contraception Rule
• Shionogi Scuttled Deal By Destroying Fenoglide Pills: Suit
• USPTO Gene Test Fight Pits Patients Against Patents
• WTC Panel To Back Cancer Coverage For 9/11 Victims: CDC
• Sens. Demand Info From Ben Venue Over Drug Shortage
• Genzyme Recalls Leukemia Meds Over Factory Concerns
• Avoiding Union Ire With Consistent Policy Enforcement
• Ex-Olympus Chief, 6 Others Arrested Over Accounting Scheme
• Calif. High Court Takes Up Cipro Pay-For-Delay Suit
• GAO Favors Protesters In Row Over $92M Medicare Contract
• HHS Delays ICD-10 Coding Switch Due To Provider Complaints
• Jury Awards Promega $52M In Genetic Test Kit IP Suit
• 7th Circ. Paves Way For More Antitrust Actions Over Tie-Ups
• Probe Into FDA Monitoring Of Whistleblower Emails Expands
• 3rd Circ. Trims Injunction In Stryker Employee Poaching Suit
• Ky. Court Shuts Down Class Cert. In Vioxx Fraud Action
• M&A Pro Jumps To Arnold & Porter From Allen & Overy
• GOP Signals Fight Ahead Over Medical Device User Fees
• Canopy Co-Founder Gets 13 Years For $93M Investment Scam
• NY To Examine Insurers' Data Used To Request Rate Hikes
• NuVasive Can't Boot Patent After $101M Infringement Verdict
• Illumina Investors Claim Goldman Bias In Suit Over Roche Bid
• Graceway Settles Claims With GTCR For $6M
• HHS, DOJ Recoup Record $4.1B From Health Fraud In FY 2011
• Judge Stays Pa. Hospital Antitrust Suit Amid Bias Claims
• Lawmakers Press FDA To Get Tough On Drug Trial Reporting
• Counterfeit Avastin Found In US, Roche Says
• Cell Therapeutics Settles Investor Lawsuit For $19M
• EDG Partners Closes 2nd Health Care Fund At $178M
• Genzyme, Insurer Settle Coverage Suit Over $64M Deal
• CMS Floats 60-Day Medicare Overpayment Refund Rule
• McKesson Can't Duck FCA Suit Over Alleged Kickbacks
• Bradley Arant Snags 4 Attys For Ala.
• AlloDerm Insurer Sues Over Coverage For Alleged Injuries
• 31 Groups Call On US To Settle Guatemala STD Case
• 'Independent Practice,' Collective Enforcement
• Waste Not, Risk Not
• Omnicare Dodges Investor Action Over Kickback Claims
• Biogen To Spend $75M For Fibrosis Drug Co. Stromedix
• Insurer Wants Out Of J&J Supplier's Bug Infestation Suit
• Facebook, Others Weigh In On Fed. Circ. Intervening Rights Case
• Obama Budget Would Trim Health Entitlements By $350B
• Obama's 2013 Budget Targets Pay-For-Delay Deals
• Dental Device Maker Halts Operations Amid FDA Warnings
• Judge OKs 3 New Bellwethers In NuvaRing MDL
• Former DOJ Atty To Lead Bass Berry's DC Office
• Drug Industry Balks At Obama's Budget Proposals
• Medtronic Pushes For Royalties In NuVasive Patent Row
• RI Hospital Puts Up $5M To End False Claims Allegations
• US, 4 States Join CVS Caremark Insurance Fraud Action
• Weil Gotshal Grabs Dechert Litigation Duo For NY Office
• Express Scripts, Medco Send FTC More Info On $29B Merger
• Kirkland & Ellis Helps Linden Buy SeraCare For $82M
• Mylan Must Shell Out $18M To Sunovion In Xopenex Patent Suit
• Delays Cost Cephalon TRO In Anti-Epilepsy Patent Suit
• Biosimilar Guidance Silent On Industry's Biggest Questions
• Fed Circ. Upholds $371M Award In Bard Graft Patent Suit
• Nautilus Falsely Marked Exercise Equipment: Judge
• Merck, Bayer Target Watson Over Generic Beyaz Birth Control
• Mylan Escapes 6 Cases In Darvocet, Darvon MDL
• US Sues Dallas Drug Compounder Over 3 Colchicine Deaths
• Pfizer Bests Investor Suit Over Alzheimer's Drug Trial
• 5th Circ. Won't Rehear Texas Abortion Law En Banc
• Scrushy Appeals Bribery Conviction To Supreme Court
• Patient Wants High Court To Take Up Genzyme Negligence Suit
• Judge Says MediSys Wage Suit Should Be Tossed
• Jackson Lewis Gets New Partners In Boston, NYC
• Sens. Press OMB For Delayed Medical Device Rule
• Judge Misread Patent Claims, Sanofi Tells Fed. Circ.
• Obama Announces Compromise On Birth Control Rule
• Whistleblower Settles Blackstone FCA Kickback Claims
• A Green Light For Repetitive Class Action Litigation
• Revised Removal Statutes — Possibilities, Pitfalls: Part 2
• Jury Clears Sigma In $172M Medical Pump Patent Suit
• Espada Accuses Gov't Of Misconduct In Record Seizure
• Health Insurers Slam HHS Rule To Simplify Policy Explanations
• Case Study: Messner V. Northshore
• FDA Releases Guidance On Biosimilar Approvals At Last
• Ex-Leo Pharma Sales Reps Launch OT Class Action
• Feds Seek 15 Years For Ex-Canopy Exec's $93M Fraud Role
• Ex-Allergan President Escapes Investor Suit Over Exec Pay
• AstraZeneca Can't Block Generic Crestor: Fed. Circ.
• Covington Scores Wilson Sonsini Corporate Team
• 9th Circ. Axes Lawsuit Over Stores' Drug Pricing Role
• Drug Cos. To Fund FDA Generics Reviews Under New Bill
• Catholic TV Network Sues US Over Birth Control Mandate
• Business Associates Beware: Accretive's HIPAA Suit
• Ex-Takeda Exec Settles SEC Insider Trading Claims
• Ex-Citigroup Exec Hits Abbott With Humira Cancer Suit
• Doughty Hanson Picks Up Spanish Hospital Group For $472M
• No Quick Win For Ex-KV Pharma CEO On Criminal Costs
• How They Won It: Ropes & Gray Rescues Stryker Biotech
• FDA Panel Votes Against Amgen's Xgeva For Prostate Cancer
• Drug Co. Dava Pays $11M To End Medicaid Rebate Suit
• Ernst & Young Censured, Fined $2M Over Faulty Audits
• Continental Ducks Coverage For $198M Anthem Settlement
• Mylan Can't Launch Doryx Generic Just Yet
• Popular Acid Reflux Drugs Can Trigger Infections: FDA
• Insurer Dodges Malpractice Liability Over Unfiled Suit
• PE's Healing Touch Faces Test In Hospital Buys
• FDA Faces Renewed Battle Over Plan B Age Restrictions
• Watson, J&J Settle Over Birth Control Generic
• Qui Tam Trends In 2011, Predictions For 2012
• Benefit Corps. — A New Structure For The New Economy
• Illumina Board Urges Investors To Reject $6B Roche Bid
• Feds Worried Over Espada Atty's Conflicts Of Interest
• Fed. Circ. Finds Exception To Late Interference Claims
• Bayer, Merial Flea Product Class Actions Merged In Ohio
• Hospitals Will Pay DOJ $12M To End Medicare Fraud Claims
• DC Circ. Says Seniors Can't Disown Medicare Eligibility
• IP Attys Blast USPTO's Supplemental Exam Rules
• Bingham Aids Platinum Equity's Medical Equipment Co. Buy
• MDL Panel Sends Surgical Mesh Battles To W.Va.
• MGH Didn't Credit Researchers For Patents, Fed. Circ. Hears
• BioMed Realty Brings In Mass. Office Space For $119M
• Judge Upholds FDA Approval Of Generic Lovenox
• MoFo Adds Howard Hughes GC To Life Sciences Team
• DOL Tells High Court Drug Sales Reps Deserve OT Pay
• A Real Headache Of A Disability Claim
• Pfizer Faces Antitrust Suit Over Generic Lipitor Delay
• Judge Can't Stop Contentious Texas Abortion Law
• Health Mandate Violates Constitution, Critics Tell High Court
• Fed. Circ. Lifts Lupin Ban In Generic Fortamet Fight
• Wake Forest Blasts Jury Interrogatories In Fed. Circ. IP Case
• ProMedica Begs FTC Not To Make It Divest Ohio Hospital
• 5th Circ. Leaves Insurers On Hook In Ambulance Injury Suit
• Ranbaxy Exits Pfizer's Suit Over Generic Rapamune
• Greenberg Adds Reed Smith Atty To Health Products Group
• RiverVest Investor Payouts Off $1B Sales Top Charts
• Mylan, Shire Battle Again Over Generic Vyvanse
• IRS Lays Out Plan For New Medical Device Tax
• Who's A Federal Contractor? You Just Might Be
• Smith & Nephew Pays $22M To Settle US Bribery Allegations
• BioSante Female Libido Drug Hype Was Fraudulent: Suit
• Vitamin Buyers Get Class Cert. In Bayer Prostate Health Case
• DOJ, McDermott Call Quits On Hospital Merger FOIA Suit
• Attys' Fees Sink Proposed Adventist FLSA Settlement
• Cancer Drug Firm Duped Investors In $26M Offering: Suit
• Sen. Looks To Close Cost Gap In Hospitals' Implant Buys
• Columbia Labs Sued Over Drug-Related Stock Drop
• Quest Asks 2nd Circ. To Bar Ex-Atty From Kickback Suit
• GAO Scraps Protests Over $73M Medicare Auditing Contract
• Wheelchair Fraud Prevention Programs To Launch In June
• Trends In M&A, Spin-Offs, Hostile Deals And PE
• FTC Won't Get Monitor For ProMedica Hospital Operations
• Impax, Teva Put Generic-Wellbutrin MDL To Bed
• Senate Bill Would Streamline FDA's New Device Reviews
• 7th Circ. Shuts Down Abbott Workers' Benefit Appeal
• NLRB Wrongly Awarded Nurses Back Pay, DC Circ. Hears
• Highlighting 'Pay For Delay' Concerns
• A Little 'Guidance': All You Need For Preemption?
• Revised Removal Statutes — Possibilities, Pitfalls: Part 1
• Health Info Services Co. Jobson Heads To Ch. 11
• EU Seeks Deeper Study Of Faulty Breast Implants
• DLA Piper Snags McDermott Health Care Team
• 7 Convicted In NY Presbyterian Hospital Kickback Plot
• Grassley Grills FDA Over Whistleblower Treatment
• Dentsply Blames Lewis & Roca For Contract Case Loss
• Sen. Blasts Express Scripts, Medco Deal On Antitrust Fears
• Angioblast Loses Contract Counterclaims Against UBS
• CMS Won't Change Emergency Care Rules For Inpatients
• Ex-Reed Smith Life Sciences Pro Jumps To Hogan Lovells
• Bill Targets 'Loophole' In FDA Device Approval Process
• TheraMax Cold And Flu Can't Treat Either Ailment: Suit
• Witness Must Testify In Medtronic Off-Label Suit: Judge
• Plastic Surgeons In Italy Sue Over Faulty Breast Implants
• Kappos Says Prior Use Rule Shouldn't Be Changed For Now
• Astellas Can't Shake MDL Over Generic Prograf Delays
• House To Subpoena VA Docs Over Off-Contract Drug Buys
• 5th Circ. Allows State Claims In Stryker Implant Suit
• FDA Aims To Boost Inspections Of Foreign Drugmakers
• Davis Polk Nabs Former Deputy AG
• Pfizer Recalls Birth Control Pills After Packaging Mix-Up
• Mitigating Risk In Mass Nano Torts
• The Importance Of Legal Audits
• The Global Reach Of Stem Cell Research Patents
• Territory Managers Hit Quest With Wage Class Action
• Crowell Adds 3 Kilpatrick Townsend Drug IP Specialists